"\u003Chtml\u003E\n \u003Chead\u003E\u003C\u002Fhead\u003E\n \u003Cbody\u003E\n \u003Cdiv\u003E\n \u003Cdiv\u003E\n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Ch2\u003E\u003Cp\u003E‘This is the first drug that provides a real treatment option,’ says leading researcher \u003C\u002Fp\u003E\u003C\u002Fh2\u003E \n \u003C\u002Fdiv\u003E \n \u003Cfigure\u003E\n \u003Cspan class=\"view-HD-pictures-wrap\"\u003E\n \u003Cimg class=\"view-HD-pictures\" data-src=\"https:\u002F\u002Fres.6chcdn.feednews.com\u002Fassets\u002Fv2\u002Fd69542b2b84b38774eb9b1193d2d7632?source=nlp&quality=uhq&format=jpeg&resize=720\" alt=\"\u003Cp\u003E\n \u003Cspan class=\"view-HD-pictures\"\u003EView pictures in App save up to 80% data.\u003C\u002Fspan\u003E\n \u003C\u002Fspan\u003EThe drug targets protein cells called amyloid which clump together to form harmful plaques associated with Alzheimer’s \u003C\u002Fp\u003E\" data-image-width=\"320\" data-image-height=\"726\"\u003E\n \u003Cfigcaption\u003E\n The drug targets protein cells called amyloid which clump together to form harmful plaques associated with Alzheimer’s\n \u003C\u002Ffigcaption\u003E\n \u003C\u002Ffigure\u003E \n \u003C\u002Fdiv\u003E \n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Cp\u003EScientists are hailing a historic step in the fight against Alzheimer’s, after a drug was proven to slow the disease in long-awaited clinical trials.\u003C\u002Fp\u003E \n \u003Cp\u003EThe breakthrough comes after decades of failed attempts to find a way to do so, and has prompted hope among experts that it could eventually pave the way for treatments which could ultimately lead to a cure.\u003C\u002Fp\u003E \n \u003Cp\u003EThe drug is an antibody therapy known as lecanamab, and works to remove a toxic protein known as amyloid which builds up in the brains of those with Alzheimer’s and damages cells, leading to the memory loss and communication issues associated with \u003Ca href=\"https:\u002F\u002Fwww.independent.co.uk\u002Ftopic\u002Fdementia\"\u003Edementia\u003C\u002Fa\u003E.\u003C\u002Fp\u003E \n \u003Cp\u003EThe eagerly-awaited findings of a trial – involving nearly 1,800 people aged between 50 and 90, who had been diagnosed with early Alzheimer’s – were unveiled on Tuesday night in San Francisco and in the \u003Cem\u003ENew England Journal of Medicine\u003C\u002Fem\u003E.\u003C\u002Fp\u003E \n \u003Cp\u003EScientists found that lecanamab, when delivered as an intravenous drip every fortnight, slowed memory decline by 27 per cent over 18 months. While the disease still progressed in those taking the drug and those given a placebo, it did so significantly more slowly among the 50 per cent of participants given lecanemab.\u003C\u002Fp\u003E \n \u003Cp\u003EThe severity of their dementia was assessed using a clinical scale which measured symptoms such as forgetfulness, problem-solving skills and their ability to live independently. \u003C\u002Fp\u003E \n \u003Cp\u003EScientists also used blood tests and brain scans to search for levels of amyloid among the participants – discovering that they had fallen so significantly in those given lecanemab that some patients no longer technically met the threshold for an Alzheimer’s diagnosis.\u003C\u002Fp\u003E \n \u003Cp\u003EAlzheimer’s is the most common cause of dementia, and the conditions are the leading cause of death in the UK. Dementia is estimated to cost the UK almost £25bn each year, a cost expected to nearly double by 2050.\u003C\u002Fp\u003E \n \u003Cp\u003E“This is the first drug that provides a real treatment option for Alzheimer’s patients,” Bart De Strooper, director of University College London’s (UCL) UK Dementia Research Institute told \u003Cem\u003EThe Guardian\u003C\u002Fem\u003E.\u003C\u002Fp\u003E \n \u003Cp\u003E“While the clinical benefits appear somewhat limited, it can be expected that they will become more apparent over time.”\u003C\u002Fp\u003E \n \u003Cp\u003EProfessor Nick Fox, director of UCL’s Dementia Research Centre, told the paper: “I believe it confirms a new era of disease modification for Alzheimer’s disease. An era that comes after more than 20 years of hard work on anti-amyloid immunotherapies.”\u003C\u002Fp\u003E \n \u003Cp\u003ELecanemab is produced by Biogen in the US and Eisai in Japan. The latter was reported by \u003Cem\u003EBloomberg\u003C\u002Fem\u003E on Tuesday as saying that the drug was not to blame for the deaths of two people which occurred during the trial and its extension period, after it was reported that a woman died from brain haemorrhage.\u003C\u002Fp\u003E \n \u003Cp\u003EThe company said that all available safety information indicates lecanemab therapy is not associated with an increased risk of death overall, and said it could not provide any information about specific patients “to protect the privacy of patients”.\u003C\u002Fp\u003E \n \u003Cp\u003ESome scientists \u003Ca href=\"https:\u002F\u002Fwww.science.org\u002Fcontent\u002Farticle\u002Fsecond-death-linked-potential-antibody-treatment-alzheimer-s-disease\"\u003Esuggested\u003C\u002Fa\u003E it was possible that lecanemab could raise the risk of bleeding, and cautioned against the use of blood thinners with the drug.\u003C\u002Fp\u003E \n \u003C\u002Fdiv\u003E \n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Ch3\u003ERegister for free to continue reading\u003C\u002Fh3\u003E \n \u003C\u002Fdiv\u003E \n \u003Cdiv\u003E \n \u003Cp\u003ERegistration is a free and easy way to support our truly independent journalism\u003C\u002Fp\u003E \n \u003Cp\u003EBy registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists\u003C\u002Fp\u003E \n \u003C\u002Fdiv\u003E \n \u003Cp\u003EAlready have an account? sign in\u003C\u002Fp\u003E \n \u003C\u002Fdiv\u003E \n \u003Cdiv\u003E \n \u003Cdiv\u003E \n \u003Ch3\u003ERegister for free to continue reading\u003C\u002Fh3\u003E \n \u003C\u002Fdiv\u003E \n \u003Cdiv\u003E \n \u003Cp\u003ERegistration is a free and easy way to support our truly independent journalism\u003C\u002Fp\u003E \n \u003Cp\u003EBy registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists\u003C\u002Fp\u003E \n \u003C\u002Fdiv\u003E \n \u003Cp\u003EAlready have an account? sign in\u003C\u002Fp\u003E \n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E \n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fdiv\u003E\n \u003C\u002Fbody\u003E\n\u003C\u002Fhtml\u003E"